Please click on the Activation Link to activate your account.
If you don't receive our email, please check your spam folder.
|Objective:||To investigate whether the relationship between elevated triglycerides and low HDL-C (atherogenic dyslipidaemia) and cardiovascular risk depends on glycaemic dysregulation, sex, or low-density lipoprotein cholesterol (LDL-C) levels.|
|Study design:||Community-based, prospective cohort study of American Indians who were enrolled between 1989 and 1991 (median follow-up 17.7 years).|
|Study population:||3,216 individuals (mean age 56 years, 40% men, 41% with diabetes) who were free of cardiovascular disease (CVD) at baseline.|
|Efficacity measures:||Primary endpoint: incident cardiovascular events, defined as fatal or nonfatal ischaemic stroke and coronary heart disease (CHD), identified by annual morbidity and mortality surveillance.
Secondary endpoints: Lipid parameters
Fasting triglycerides, categorized as normal (<150 mg/dL) or high (≥150 mg/dL)
Fasting HDL-C levels, categorized as normal (≥40 mg/dL for men and ≥50 mg/dL for women) or low (<40 mg/dL for men and <50 mg/dL for women)
|Methods:||Triglycerides-HDL-C status was categorized using the above criteria. Cox proportional models controlling for age, sex, body mass index, smoking, diabetes, fasting LDL-C level, use of antihypertensive medications, physical activity, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio, were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident ischaemic stroke and CHD in relation to combined triglycerides and HDL-C status. A p-value for interaction of 0.05 was considered statistically significant for effect modification.?|
Table. Impact of high triglycerides-low HDL-C dyslipidaemia on risk for cardiovascular events, fully adjusted model
Hazard ratio versus reference, i.e. normal triglycerides and normal HDL-C levels
|Authors’ conclusion:||American Indian adults with both high triglycerides and low HDL-C, particularly those with diabetes, have increased risks of incident CHD and stroke.|
Consistent with this month’s theme, this report from the Strong Heart Study provides evidence that the combination of elevated fasting triglycerides and low HDL-C, atherogenic dyslipidaemia, is associated with increased cardiovascular risk in American Indians, especially in those with diabetes. Thus, the study adds evidence that reaffirms the link between atherogenic dyslipidaemia and cardiometabolic risk across the range of ethnic groups.1
These findings are important in the context of the characteristics of this cohort. American Indians are known to have disproportionately high rates of obesity and diabetes, when compared with European populations.2 While a previous report highlighted elevated LDL-C as a risk factor for CHD in this cohort,3 the current report emphasises the importance of lipid factors beyond LDL, notably atherogenic dyslipidaemia, as contributors to this risk. Moreover, the study shows that it is the dysregulation of glycaemia (and/or the underlying factors leading to hyperglycaemia), rather than other causes, that drive this risk in individuals with atherogenic dyslipidaemia.
Taken together, these findings highlight the importance of recognizing atherogenic dyslipidaemia in insulin resistant and/or hyperinsulinaemic patient groups and targeting this dyslipidaemia with appropriate therapeutic strategies. Fibrates may represent one option currently available, as shown by a meta-analysis of the major fibrate trials,4 although given the limited potency of these agents due to dose-related adverse effects, novel approaches are also needed.
|References||1. McQueen MJ, Hawken S, Wang X et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33.
2. Zhao Q, Zhu Y, Best LG et al. Metabolic profiles of obesity in American Indians: The Strong Heart Family Study. PLoS One. 2016 Jul 19;11(7):e0159548.
3. Xu J, Lee ET, Peterson LE et al. Differences in risk factors for coronary heart disease among diabetic and nondiabetic individuals from a population with high rates of diabetes: the Strong Heart Study. J Clin Endocrinol Metab 2012 ;97:3766-74.
4. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692–5.
|Key words||residual cardiovascular risk; diabetes; atherogenic dyslipidaemia; Strong Heart Study|